Jubilant Ingrevia To Acquire 40% Stake In Deep-Tech Firm Zettaone Technologies For Rs 189 Crore

Specialty chemicals maker Jubilant Ingrevia's board has approved entry into a binding term sheet to acquire a 40% strategic equity stake in Zettaone Technologies India, an electronics design and manufacturing company, for a total consideration of Rs 189.2 crore. The announcement was among the stocks to watch on Dalal Street on Wednesday, with shares of Jubilant Ingrevia drawing investor attention through the session.

Inside The Deal

Zettaone Technologies operates as an electronics design and manufacturing platform with integrated capabilities spanning the electronics and semiconductor value chain. The company, co-founded by Harikrishnan, Sureshkumar, Prabu and Arunkumar, provides engineering services for aerospace, defence, semiconductor, automotive, medical and industrial applications. Once the transaction closes, Zettaone will become an associate company of Jubilant Ingrevia rather than a wholly owned subsidiary, reflecting the 40% stake structure.

Jubilant Ingrevia has framed the investment as a strategic move to extend its footprint beyond its traditional chemicals and life sciences businesses into electronics development and manufacturing services, an area the company sees as complementary to its existing contract development and manufacturing organisation (CDMO) operations.

Strategic Rationale

Company management said the acquisition is designed to help Jubilant Ingrevia capitalize on Zettaone's manufacturing and customer-centric capabilities while deepening its engagement with customers across the electronics and semiconductor supply chain. The move is being positioned as part of the company's broader "Pinnacle" growth strategy, which has emphasized diversification into higher-value, technology-adjacent businesses in recent quarters.

Electronics manufacturing and semiconductor-linked services have become an increasingly active area for Indian industrial and chemicals conglomerates looking to tap into the government's push for domestic electronics production and reduced import dependence in critical technology components.

Market Reaction

The announcement featured prominently in Wednesday's stocks-to-watch lists alongside other closely tracked names, as investors weighed the implications of Jubilant Ingrevia's diversification push. The stock has seen periods of strong momentum earlier in the year on the back of its chemicals and pharmaceutical intermediates business, and the Zettaone stake adds a new growth vector for analysts to factor into valuations.

What's Next

The transaction remains subject to the completion of definitive documentation and customary regulatory and closing conditions following the binding term sheet. Jubilant Ingrevia has not disclosed a specific timeline for closing, though such strategic minority-stake deals in India typically complete within one to two quarters once term sheets are finalized. Investors will be watching subsequent regulatory filings for further financial and operational details on Zettaone, including its revenue base and growth trajectory, as the deal progresses toward completion.

This article is an original editorial summary based on publicly reported information. It has been independently written for publication and does not reproduce content from any single source.